Postoperative Hormonal Therapy and Recurrence After Surgery for Ovarian Endometrioma

NCT07519213 | Completed

• 1 other identifier: GuangdongWCH-Li Li04
• Study Type: observational
• Target: 1,121
• Locations: 1 country
• Sites: 1

Brief Summary

This retrospective cohort study evaluates the association between postoperative hormonal treatment and recurrence of ovarian endometriosis in women undergoing surgery for ovarian endometrioma. The study includes patients treated at a single center who initiated one postoperative hormonal regimen after surgery. The main objective is to compare the risk of recurrence among women receiving combined oral contraceptives, gonadotropin-releasing hormone agonists, dienogest, or dydrogesterone. Recurrence is assessed during follow-up based on postoperative clinical and ultrasound findings. The results may help clarify the comparative effectiveness of commonly used postoperative hormonal strategies for reducing recurrence after surgery for ovarian endometrioma.

Conditions

Ovarian Endometrioma; Endometriosis

Keywords

postoperative hormonal therapy; recurrence; conservative surgery; combined oral contraceptives; gonadotropin-releasing hormone agonist; dienogest; dydrogesterone; retrospective cohort

Outcome Measures

Primary Outcomes (1)

• Recurrence of ovarian endometrioma within 2 years after surgery

  Recurrence is defined as a newly detected ovarian cyst measuring at least 2 cm on ultrasound and documented on at least 2 separate examinations during follow-up.

  Within 2 years after surgery

Study Arms (4)

COC

Participants who received combined oral contraceptives as postoperative hormonal therapy in routine clinical practice after surgery for ovarian endometrioma.

GnRH-a

Participants who received gonadotropin-releasing hormone agonists as postoperative hormonal therapy in routine clinical practice after surgery for ovarian endometrioma.

DNG

Participants who received dienogest as postoperative hormonal therapy in routine clinical practice after surgery for ovarian endometrioma.

Dydrogesterone

Participants who received dydrogesterone as postoperative hormonal therapy in routine clinical practice after surgery for ovarian endometrioma.

Eligibility Criteria

• Age: 18 Years - 45 Years
• Sex: female
• Healthy Volunteers: No
• Age Groups: Adult (18-64)
• Sampling Method: Non-Probability Sample

Study Population

Women with ovarian endometrioma who underwent conservative surgery at a single study center and subsequently received postoperative hormonal therapy in routine clinical practice.

You may qualify if:

• Female patients who underwent conservative surgery for ovarian endometrioma at the study center.
• Initiation of one postoperative hormonal regimen within 1 month after surgery.
• Continuous use of the same single hormonal regimen for at least 6 months after surgery.
• Availability of clinical records and postoperative follow-up data for assessment of study outcomes.

You may not qualify if:

• Failure to initiate postoperative hormonal therapy within 1 month after surgery.
• Discontinuation of the postoperative hormonal regimen before 6 months.
• Use of sequential or multiple postoperative hormonal therapies during the initial treatment period.
• Incomplete clinical records or insufficient follow-up data for evaluation of recurrence.

Sponsors & Collaborators

• Guangdong Women and Children Hospital: lead

Study Sites (1)

Guangdong Women and Children Hospital

Guangzhou, Guangdong, 511400, China

Location

Related Publications (3)

• Schrager S, Yogendran L, Marquez CM, Sadowski EA. Adenomyosis: Diagnosis and Management. Am Fam Physician. 2022 Jan 1;105(1):33-38.

  PMID: 35029928 BACKGROUND

• As-Sanie S, Mackenzie SC, Morrison L, Schrepf A, Zondervan KT, Horne AW, Missmer SA. Endometriosis: A Review. JAMA. 2025 Jul 1;334(1):64-78. doi: 10.1001/jama.2025.2975.

  PMID: 40323608 BACKGROUND

• Becker CM, Bokor A, Heikinheimo O, Horne A, Jansen F, Kiesel L, King K, Kvaskoff M, Nap A, Petersen K, Saridogan E, Tomassetti C, van Hanegem N, Vulliemoz N, Vermeulen N; ESHRE Endometriosis Guideline Group. ESHRE guideline: endometriosis. Hum Reprod Open. 2022 Feb 26;2022(2):hoac009. doi: 10.1093/hropen/hoac009. eCollection 2022.

  PMID: 35350465 BACKGROUND

MeSH Terms

Conditions

Endometriosis; Recurrence

Condition Hierarchy (Ancestors)

Genital Diseases, Female; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Genital Diseases; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Professor

Study Record Dates

• First Submitted: April 2, 2026
• First Posted: April 9, 2026
• Study Start: September 1, 2025
• Primary Completion: January 1, 2026
• Study Completion: January 1, 2026
• Last Updated: June 1, 2026

Record last verified: 2026-05

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)